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Abstract
Vascular endothelial dysfunction is one of the earliest recognizable events under
hyperglycemic conditions. It is characterized by decreased endothelium-derived nitric
oxide (NO) bioavailability and increased oxidative stress, such as superoxide and
hydrogen peroxide (H2O2) overproduction. However, the real-time changes in blood NO
and H2O2 levels under acute hyperglycemia have not been evaluated. In this study, acute
hyperglycemia (200 mg/dl, 400 mg/dL, and 600 mg/dL) was induced by intravenous
infusion of 20%, 30%, and 50% D-glucose respectively for 180 min. Infusion of saline or
30% L-glucose serve as controls. Blood NO or H2O2 levels were measured at real-time
by inserting calibrated NO or H2O2 microsensors (100 µm diameter) into each femoral
vein, respectively. In the saline group, blood NO levels remained stable and only slightly
decreased by 17.61±8.04 nM (n=7) at 180 min compared to baseline. By contrast,
hyperglycemia significantly decreased blood NO levels from 100-160 min to the end of
the experiment. At 180 min, blood NO levels in 200 mg/dL, 400 mg/dL, and ≥600
mg/dL groups were 71.3±17.9 nM (n=7), 112.15±15.28 nM (n=6), and 105.98±23.45 nM
(n=6) lower than that in saline group, respectively (all p<0.01). However, there was no
significant difference in blood NO levels between L-glucose group and the saline control
throughout the entire experiment. Blood NO levels were only 11.58±22.01 nM (n=5)
higher compared to the saline control at 180 min of infusion of 30% L-glucose.
Meanwhile, blood H2O2 levels in saline group continued to drop and reduced by
4.62±0.34 µM (n=5) at the end of the 180 min infusion compared to the baseline. By
contrast, hyperglycemia significantly increased blood H2O2 levels from 20-60 min, then
stayed higher throughout the rest of the experiment. At 180 min, blood H2O2 levels in
200 mg/dL, 400 mg/dL, and 600 mg/dL groups were 2.40±0.61 µM (n=6), 3.1±0.2 µM
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(n=6), and 2.21±0.37 µM (n=6) higher than that in saline group, respectively (all p<0.01).
However, blood H2O2 levels in L-glucose group remained similar level as saline control
throughout the experiment. The blood H2O2 levels were only 0.88±0.29 µM higher in the
L-glucose group (n=5) compared to the saline control at the end of the experiment. In
summary, this acute hyperglycemia rat model exhibits vascular endothelial dysfunction
by presenting significantly lower blood NO levels and significantly higher blood H2O2
levels, which is not principally due to hyperosmolarity.
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1
Introduction

Hyperglycemia and Vascular Complications
The conditions of hyperglycemia has been emphasized in many diseases, such as
diabetes, metabolic syndromes, and some post-surgery complications (FatehiHassanabad, Chan et al.; Ceriello, Hanefeld et al. 2004; Ceriello 2005; Forstermann
2010). There is considerable evidence indicating that both acute and chronic
hyperglycemia have deleterious effects on vascular function and are closely related to
micro and macro vascular complications. However, the mechanisms underlying
hyperglycemia-induced vascular and organ damage are complex and unclear. Therefore,
it is critical to understand mechanisms involving vascular endothelial dysfunction under
hyperglycemic conditions for identifying and ultimately developing new treatment
strategies to attenuate the detrimental effects of hyperglycemia.

1. Clinical Hyperglycemia Conditions
In normal human subjects, the concentration of fasting whole blood glucose is
around 101 mg/dL. Hyperglycemia occurs when an individual’s blood glucose level
exceeds 126 mg/dL. If hyperglycemia persists after at least an 8 hr overnight fast, a
diagnosis of diabetes is made. Fasting blood glucose within 110 to 124 mg/dL is
recognized as impaired fasting glucose (Gardner and Shoback 2007). The oral glucose
tolerance test is another way to diagnose diabetes. This test requires an individual to
receive 75 g of glucose solution and then wait for 2 hours, then the blood glucose levels
will be checked. If an individual’s blood glucose levels exceed 180 mg/dL, then a
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diagnosis of diabetes is made. Two-hour postprandial blood glucose levels between 121178 mg/dL are considered as impaired glucose tolerance. When the blood glucose is
about 200 mg/dL (i.e. mild hyperglycemia), patients begin to exhibit the symptoms of
hyperglycemia including excessive thirst, polydipsia, headaches, fatigue and blurred
vision (Forstermann and Munzel 2006; Gardner and Shoback 2007; Forstermann 2010).
Ketoacidosis is a complication of diabetes that occurs when the body cannot use glucose
as a fuel source due to insufficient amount of insulin in the body, and fat is utilized
instead. This affects individuals with a blood sugar level above 600 mg/dL. This severe
hyperglycemia can cause weakness and may progress to coma or even death. When blood
glucose is 700 mg/dL or higher, it can induce hyperglycemic hyperosmolar syndrome
with more viscous blood due to the excess glucose in the blood and may result in brain
damage (Ceriello 2005).

2. Acute Hyperglycemia in Non-Diabetic Subjects
In non-diabetic subjects, blood glucose levels may increase under some
conditions such as after a high glucose diet (i.e., oral glucose test), stress, post-surgery,
medicine, and critical illness (Finney, Zekveld et al. 2003; Falciglia, Freyberg et al. 2009;
Sato, Carvalho et al. 2010). Clinically, fasting plasma glucose and postprandial (2 hours
after meal) glucose levels or oral glucose tolerance test often have been used to indicate
the acute hyperglycemia level.
Both critical illness and postoperative status are accompanied with so-called
stress-induced hyperglycemia. It is a transient hyperglycemia during illness rather than
from previous diabetes mellitus (Dungan, Braithwaite et al. 2009). Evidence indicates
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that stress-induced hyperglycemia in critically ill and preoperative patients serves as an
independent marker of poor outcomes, such as infection, slow recovery, and higher
mortality (Finney, Zekveld et al. 2003; Falciglia, Freyberg et al. 2009; Sato, Carvalho et
al. 2010). If hyperglycemia is left uncontrolled, it can lead to hypokalaemia,
hypoatraemia, arrhythmias and an increased risk of ischemic brain injury (Hogue, 2006).
Also hyperglycemia may predispose patients to an increased risk of post-surgical
infections through impaired phagocytic activity and decreased neutrophil function
(Rassias, Marrin et al. 1999; Hanazaki, Maeda et al. 2009). Due to the possible danger
caused from hyperglycemia, it is important to make sure that patients maintain a normal
blood glucose at all times. Published evidence suggests blood glucose less than
110mg/dL in critically ill, surgical and non-surgical patients, reduces morbidity and
mortality (van den Berghe, Wouters et al. 2001).
Some studies have linked the role of acute hyperglycemia to the development of
vascular complications in non-diabetic individuals (Forstermann and Munzel 2006). It
suggests that even in the absence of clinically diagnosed diabetes, high dietary glucose
consumption and postprandial hyperglycemia are associated with an increased risk of
cardiovascular disease (Ceriello, Hanefeld et al. 2004). Hanefeld et al. have linked
postprandial hyperglycemia levels in nondiabetic patients with the incidence of
mediointimal carotid thickening. In a study containing 403 participants, Hanefeld noted a
correlation between significant intima-media thickness in the carotid arteries of non
diabetic individuals and within the 2 hour postprandial glucose spiking (Hanefeld,
Koehler et al. 1999). Further evidence suggest that postprandial glucose levels are
associated with increased production and disturbed removal of triglyceride-rich
lipoporteins, impaired fibrinolysis and oxidative stress. Hanefeld et al. suggested that
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postprandial hyperglycemia with oxidative stress may have damaging effects on the
arterial wall and could accelerate atherosclerosis. It also has been suggested that most
cardiovascular risk factors may be modified in the postprandial phase and are directly
affected by an acute increase in blood glucose. One of the primary mechanisms is that
acute hyperglycemia may cause the overproduction of free radicals, which favors the
development of vascular endothelial dysfunction (Ding, Aljofan et al. 2007).

3. Chronic Hyperglycemia/Diabetes
Diabetes mellitus is one of the most common chronic diseases worldwide and is
associated with both increased morbidity and mortality. It is also characterized by chronic
hyperglycemia resulting from defects in insulin sensitivity and/or secretion associated
with different vascular complications (ADA, Diabetes Care 2007). Currently, there are
about 285 million individuals with diabetes worldwide and by the year 2030, this
prevalence is expected to increase up to 439 million globally (Wild, Roglic et al. 2004).
Long term prognosis of individuals with diabetes remains poor because of the
microvascular and macrovascular complications resulting from chronic hyperglycemia.
Diabetic microvascular complications include retinopathy, nephropathy, and
neuropathy. In 2009, the American Diabetes Association published data showing
diabetes is the leading cause of new cases of blindness and kidney failure among adults
aged 20–74 years. Moreover, about 60% to 70% of people with diabetes have mild to
severe forms of nervous system damage. Furthermore, greater than 60% of nontraumatic
lower-limb amputations occur in people with diabetes (ADA, 2009). In regard to
macrovascular complications, diabetes is characterized by high incidence of
cardiovascular diseases (Ceriello 2005). Type II diabetics are two to four times more
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likely to develop cardiovascular diseases than non diabetic individuals. Sixty-five percent
of patients with type II diabetes die from complications related to heart disease or stroke
(Rodriguez, Lau et al. 1999; Milicevic, Raz et al. 2008).
Postprandial hyperglycemia can play a key role in the pathogenesis of vascular
complications in diabetes. The clinical follow up study conducted by Meigs revealed that
fasting hyperglycemia and 2-h post-challenge hyperglycemia independently increase the
risk for cardiovascular disease, such as heart disease and stroke in diabetic patients
(Meigs, Nathan et al. 2002). Furthermore, in the Diabetes Epidemiology: Collaborative
analysis of Diagnostic criteria in Europe (DECODE) study, mortality risk of
cardiovascular disease increased with post-glucose load plasma glucose concentrations
regardless of fasting plasma glucose levels (DECODE Study Group 2001). Postprandial
hyperglycemia in type II diabetic patients has also been associated with myocardial
perfusion defects, due to the deterioration in heart microvascular function (Scognamiglio,
Negut et al. 2006). Similarly, other studies with type I diabetes patients demonstrated
that acute hyperglycemia altered myocardial repolarization and increased the stiffness of
intermediate-sized arteries (Gordon, 2007).

Hyperglycemia and Vascular Endothelial Dysfunction:
It is very important to maintain the homeostasis of vascular endothelium at resting
state for proper tissue/organ blood perfusion. Vascular endothelial can be cultivated by
various stimuli and is involved in the pathogenesis of different diseases, such as
ischemia/reperfusion injury, hyperglycemia, diabetes, and infectious diseases (Saha, Xia
et al. 2006; Pate, Damarla et al. 2010). Hyperglycemia can disturb the homeostasis of
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vascular endothelium, induce vascular endothelial dysfunction, and initiate the cascade of
vascular-organ dysfunction.

1. Normal Vascular Endothelial Function
The vascular endothelium is composed of a monolayer of endothelial cells. These
cells line the vascular system and serve as a semi-permeable barrier separating circulating
blood from the vessel wall and control the transfer of molecules between intravascular
and extravascular spaces (Sumpio, Riley et al. 2002). Normally, the vascular endothelium
stays at resting state and acts as an important regulator of vascular homeostasis (Watson,
Goon et al. 2008). Endothelial cells can also detect alterations in hemodynamic forces
and respond by synthesizing or releasing a myriad of vasoactive substances including
prostacyclin and nitric oxide (Sumpio, Riley et al. 2002; Girn, Ahilathirunayagam et al.
2007; Khazaei, Moien-Afshari et al. 2008). Therefore, under normal physiological
conditions, the vascular endothelium primarily serves to provide an antithrombotic
surface which facilitates adequate blood flow by regulating thrombosis, thrombolysis,
leukocyte adherence, platelet adherence, and vascular tone (Sumpio, Riley et al. 2002;
Girn, Ahilathirunayagam et al. 2007; Scalia 2007).

Nitric Oxide
Nitric Oxide (NO), a potent vasodilator, and is the most important vasoactive
substance produced by the vascular endothelium (Davignon and Ganz 2004). It serves as
a vasodilator to all blood vessels in the body as well as reduces inflammation. Under
normal physiological conditions, endothelial derived NO is produced by the membrane
bound enzyme endothelial nitric oxide synthase (eNOS) which oxidizes the amino acid,
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L-arginine, to form the intermediate NG-hydroxy-L-arginine (Govers and Rabelink 2001).
The two essential cofactors in this reaction are Nicotinamide-adenine-dinucleotide
phosphate (NADPH) and tetrahydrobiopterin (BH4) (Vanhoutte 2003; Channon 2004).
The oxygenase domain of eNOS contains a BH4 prosthetic group. By donating a single
electron, BH4 activates heme bound O2. This is then recaptured to enable NO release
(Verhaar, Westerweel et al. 2004). It has been indicated that L-arginine and BH4 are
critical for stabilizing the dimeration of eNOS structure for electron transfer and NO
production. Thus, eNOS normally produces NO in the presence of an essential cofactor,
BH4, by facilitating the reduction of molecular oxygen to L-arginine oxidation and
generation of L-citrulline. This reaction is referred to as eNOS coupling (See Figure 1)
(Schmidt and Alp 2007).

Figure 1. The role of BH4 in regulating eNOS activity. Endothelial NOS coupling
occurs during a normal setting allowing the reaction to produce NO and L-citrulline
from L-arginine /NADPH/O2. When uncoupled, eNOS will produce SO. Picture is
adapted from (Schmidt and Alp 2007).
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The synthesis and release of NO occur in response to stimuli acting on the
endothelial cell surface and are dependent on the intracellular calcium level (Kharbanda
and Deanfield 2001). Acetylcholine and physiological stress, such as blood flow shear
stress, can stimulate the release of NO (Vanhoutte 2003). This is accomplished by
increasing the intracellular calcium level and facilitating the production of NO from
eNOS. NO, a potent and lipophilic gas, is able to permeate cell membranes easily and
diffuse toward smooth muscle cells and into the vascular lumen (See figure 2) (Watson,
Goon et al. 2008).

+SO

Figure 2. NO production and its physiological and pathophysiological effects.

NO exerts its effect in smooth muscle cells by binding to the heme group of the
enzyme guanylyl cyclase (Al-Sa'doni and Ferro 2000). Activated guanylyl cyclase results
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in an increased production of cyclic 3’5’ guanosine monophosphate (cGMP). cGMP is an
important second messenger which results in dephosphorylation of myosin light chain
kinase (MLCK) and the activation of cGMP-dependent protein kinase. GMP-dependent
kinase phosphorylates K+ channels leading to the membrane hyperpolarization and
reduction of intracellular Ca2+ ions. These collaborative processes result in the relaxation
of smooth muscle cells (See figure 2) (Lincoln, Komalavilas et al. 1994; Kharbanda and
Deanfield 2001).
In addition to its vasodilatory ability, NO has several effects on the cardiovascular
system which include quenching superoxide radicals for its removal from the body as
well as its inhibitory effects on smooth muscle cell proliferation (Laroia, Ganti et al.
2003). NO plays an important role in preventing neutrophil adhesion, aggregation, and
activation (See figure 2) (Girn, Ahilathirunayagam et al. 2007). Kubes et al.
demonstrated that the blockade of NO production by using NG nitro L-arginine methyl
ester (L-NAME), a non-selective NO synthase inhibitor, resulted in a 15-fold increase in
leukocyte adherence and significant increase in transmigration of leukocytes in cat
mesenteric post-capillary venules (Kubes, Suzuki et al. 1991). These transmigrated
leukocytes can ultimately release SO, myeloperoxidase, elastase and cause cell and tissue
damage (Lefer, 1996). These results indicate endothelial-derived NO is an important
endogenous inhibitor of leukocyte-endothelial interactions (Kubes, Suzuki et al. 1991).
In addition to eNOS, two other isoforms of NOS enzyme exist; and each has
specific functions. Neuronal NOS (nNOS) is found in the nervous system and skeletal
muscle. NO release from nNOS is used for transmission from one neuron to another
while inducible NOS (iNOS) is found in the immune system and utilized by
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macrophages, neutrophils, and other inflammatory cells (Forstermann and Munzel 2006;
Keklikoglu 2008). Neuronal NOS and eNOS are constitutively expressed and tightly
regulated by calcium and calmodulin. The both NOS forms produce small amounts of
NO (i.e., nM range), which has precise actions on adjacent cells. In contrast, iNOS is
calcium and calmodulin independent and produces high levels of nitric oxide (i.e., µM
range) in response to inflammatory cytokines (Mungrue, Husain et al. 2002).
A small amount of NO diffuses into smooth muscle, but the majority of the NO
that does not diffuse abluminally and reacts rapidly with hemoglobin to form nitrate.
Another fraction of NO produced by eNOS in the vasculature (approximately 20%)
escapes inactivation by hemoglobin and is oxidized to nitrite (NO2−) in the plasma by
ceruloplasmin, and functions to modify proteins and lipids to form low concentrations of
N-nitrosamines, S-nitrosothiols (RSNO), and nitrated lipids. The formation of nitrite may
serve as stable storage forms of NO that may enzymatically reduced to NO by
deoxygenated hemoglobin along the physiological oxygen and pH gradient (MacArthur,
Shiva et al. 2007).

Reactive Oxygen Species (ROS)
ROS are molecules derived from oxygen including superoxide (SO), hydrogen
peroxide, and the hydroxyl radical. They are generated from NADPH oxidase, xanthine
oxidase, uncoupled eNOS, arachidonic acid metabolizing enzymes (i.e. cytochrome P450 enzymes), lipoxygenase and cyclooxygenase, and the mitochondrial respiratory chain
(Griendling 2005). Normally, they exist at low concentrations and involve physiological
roles in host defense mechanism (against infectious agents) and in a number of cellular
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signaling systems (Fatehi-Hassanabad, Chan et al.). Moreover, an intricate balance exists
between the formation of these oxidizing substances and their removal by antioxidant
mechanisms under physiological conditions (Girn, Ahilathirunayagam et al. 2007). For
example, superoxide is a very unstable compound and has a half-life of only a matter of
seconds. SO is converted to hydrogen peroxide (H2O2) by superoxide dismutase (SOD)
and subsequently converted to water by catalase to facilitate its removal from the body.
Thus, the measurement of H2O2 will serve as a good indicator of blood SO production
(Chen, Kim et al. 2010).

2. Endothelial Dysfunction and Hyperglycemia
Vascular endothelium has been considered as an essential component in
vascular/organ damage because its dysfunction is a common and early feature (Matsuda
and Hattori 2007; Schafer and Bauersachs 2008). Medical literature mostly defines
endothelial dysfunction as the impairment of endothelium-dependent vasorelaxation
caused by the loss of NO bioactivity in vessel walls (Cai and Harrison 2000), and has
been associated with increased oxidative stress (Sharma and Singh 2001). Clinically,
noninvasive assessment of endothelial function is to utilize the ultrasound to measure
blood vessel diameter and blood flow in order to evaluate vasodilators or flow-mediated
vascular endothelial-dependent vasodilation (Ceriello 2005).
Hyperglycemia is a cause of vascular endothelial dysfunction by reducing blood
NO bioavailability (Crabtree, Smith et al. 2008). An abundance of accumulated evidence
suggests that vascular endothelial dysfunction is one of earliest events induced by
hyperglycemia. The oral glucose tolerance test on healthy subjects, which simulates the
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postprandial hyperglycemia, results in a rapid reduction in endothelial-dependent
vasodilation at 1 hour and is quickly restored to the normal at 2 hour postchallenge.
Similarly, the postprandial hyperglycemia in relatively healthy subjects can acutely affect
endothelium-dependent regulation of blood flow (Triggle 2007). Furthermore, application
of BH4 to these healthy subjects reverses postprandial hyperglycemia-induced vascular
endothelial dysfunction at 1 hour (Triggle 2007). By contrast, the recovery of forearm
vascular endothelial function postchallenge is greatly slowed in diabetic patients who
have chronic hyperglycemia (Kawano, Motoyama et al. 1999).

Endothelial NOS and Hyperglycemia
Endothelial NOS coupling requires the presence of L-arginine and BH4.
However, when L-arginine is not available or BH4 is oxidized to dihydrobiopterin (BH2)
which reduces the ratio between BH4 to BH2, eNOS becomes uncoupled and produces
SO instead of NO by utilizing molecular oxygen (See Figure 1) (Crabtree, Smith et al.
2008). Although it is suggested that eNOS uncoupling can mediate the vascular
endothelial dysfunction under hyperglycemia conditions, it is still uncertain that eNOS
uncoupling is due to the insufficiency of L-arginine or reduced ratio of BH4 to BH2.

Oxidative Stress under hyperglycemia
Oxidative stress refers the process of cellular damage as a result of the
uncontrolled action of ROS (Watson, Goon et al. 2008). Oxidative stress occurs in
response to disruptions in internal homeostasis and disrupts this balance in favor of ROS
production which overcomes the body’s defense mechanisms (i.e. SOD) (Girn,
Ahilathirunayagam et al. 2007). The pathologies caused by SO are detrimental and well
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known (Fan, Sun et al. 2002). SO is known to induce cellular apoptosis and necrosis and
impairs vasodilatory responses of the vascular endothelium (Fan, Sun et al. 2002). When
present in high concentrations, superoxide can oxidize lipids (lipid peroxidation),
proteins, and damage DNA. Under conditions of oxidative stress SO can combine with
NO. This will inactivate the vasodilatory effects of NO. This process occurs at a rapid
rate of 6.7 x 109 mol/L-1-s-1 (Thomson, Trujillo et al. 1995). The new compound
produced is called peroxynitrite which is very cytotoxic and induces cell damage by
further uncoupling eNOS dimers to further produce more SO (See Figure 1). Thereafter,
endothelial dysfunction can be induced and also serves as a feedback inhibition of NO
production. (Girn, Ahilathirunayagam et al. 2007).
When endothelial cells are exposed to high glucose, SO release significantly
increases (Oak and Cai 2007; Forstermann 2010). Furthermore, many studies show that
there exists systemic oxidative stress and lipid oxidation under acute and chronic
hyperglycemic conditions (McNulty, Tulli et al. 2007). In addition to uncoupled eNOS,
another important source of SO production in vascular tissue is though the enzyme
NADPH oxidase. This enzyme is activated by high glucose via a PKC- beta dependent
process. The use of PKC-beta inhibitors have been shown to prevent hyperglycemia
induced endothelium dysfunction (Beckman, Goldfine et al. 2002). Additionally,
xanthine oxidase, NADPH oxidase of neutrophils, and mitochondrial dysfunction also are
sources for the production of SO. Therefore, anti-oxidants, such as vitamin C helps
preserve the vascular endothelial function under hyperglycemia conditions (Beckman,
Goldfine et al. 2001).
Vascular endothelial dysfunction can further initiate leukocyte-endothelial
interactions. Vascular endothelial adhesion molecules such as P-selectin and intercellular
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adhesion molecule-1(ICAM-1) are upregulated to promote leukocyte rolling, adherence
and transmigration. Furthermore, transmigrated leukocytes cause inflammatory reactions
by releasing proteases, SO, and cytokines such as tumor necrosis factor-α. This
inflammation can induce organ damage (Piwkowska, Rogacka et al.; Ceriello, Falleti et
al. 1998).

Hypothesis
It is accepted that chronic hyperglycemia induces oxidative stress and reduces
endothelial-derived NO bioavailability, which are closely related to microvascular and
macrovascular complications of diabetes. There is increasing evidence suggesting that
acute hyperglycemia, especially postprandial hyperglycemia, may increase oxidative
stress and cause vascular endothelial dysfunction in normal subjects (Inoguchi, Battan et
al. 1992; Ceriello, Hanefeld et al. 2004). However, it is still uncertain how quickly the
acute hyperglycemia can impair vascular endothelium dependent vasodilation in healthy
individuals. Some studies demonstrated that hyperglycemia from one to six hours reduces
endothelium dependent forearm circulation of healthy subjects (Williams, Goldfine et al.
1998; Title, Cummings et al. 2000; Beckman, Goldfine et al. 2001). By contrast,
according to McNulty, a single episode of acute hyperglycemia for one hour causes
systemic oxidative stress but does not affect endothelium-dependent vasodilation on
coronary circulation (McNulty, Tulli et al. 2007). In these studies, they use acetylcholine
or other vasodilators to evaluate vascular dilatory function but do not directly measure
blood NO change in real-time.
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In order to further understand the influence of hyperglycemia on vascular function
of a normal subject, it is critical to monitor blood NO and oxidative stress (i.e. H2O2) in
real-time under hyperglycemic conditions. Our lab has established a novel method for
the real-time measurement of blood NO and H2O2 from rat femoral veins (Teng, Kay et
al. 2008; Chen, Kim et al. 2010). This study aims to establish an acute hyperglycemic
animal model to evaluate the change of blood NO and H2O2 concentrations in real time.
We hypothesize that in the saline control, NO release may be slightly reduced
due to the decreased body temperature. There will be a decrease in H2O2 release. In
contrast, hyperglycemia will induce greater decrease in NO compared to saline control.
Furthermore, H2O2 release will remain at a higher level in the hyperglycemic group as
opposed to the saline group.
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Methods
NO or H2O2 Microsensor Calibration
Before performing the animal preparation, the NO or H2O2 microsensors (100 µm,
World Precision Instruments (WPI), Sarasota, FL) were calibrated as per manufacturer’s
recommendations. The specificity of the free radical microsensors is dependent on the
selective membrane covering the sensor. When NO or H2O2 in the solution or biological
fluid diffuse through the membrane, it is oxidized and an electrical (oxidation/reduction)
signal is generated of which amplitude is proportional to the free radical concentration in
the sample. Each type of sensor has a selective poise voltage important for obtaining
reliable data, with high performance Faraday shield incorporated in the sensor to
minimize environmental noise (Zhang, Ju et al. 2008).
The sensor is calibrated by constructing a standard curve using known
concentrations of the free radical of interest, enabling conversion of the electrical signal
recorded during the experiment to a molar concentration of NO or H2O2. The NO and
H2O2 microsensors soaked in 10 mL copper sulfate and 10 mL of PBS respectively to
retrieve a baseline. Moreover, the microsensors were connected with cables which were
plugged into the Apollo 4000 free radical analyzer (WPI, Sarasota, FL). For calibrating
NO microsensor, the standard solution (i.e. 100 µM) was made from 50 mL of distilled
water, 0.01 g of ethylenediaminetetraaceitic acid (EDTA) and 0.011 g of S-Nitroso-NAcetyl-D,L-Penicillamine (SNAP). SNAP is a NO donor and the efficiency is 60% when
using Cu2+. When the baseline is stable, known concentrations of SNAP (0-200 nM)
were added to the copper sulfate to generate the current-NO concentrations curve and
then calculated the calibration formula. To calibrate the H2O2 sensor, the standard (1
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mM) H2O2 solution was then added to 10 mL of PBS in a range of 0-2 µM to generate the
standard curve.
Animal Preparation
The Institutional Animal Care and Use Committee of Philadelphia College of
Osteopathic Medicine approved all animal protocols performed in this study.
Once free radical sensor calibration is complete, male Sprague-Dawley rats
ranging from 0.275-0.325 kg were anesthetized with 60 mg/kg pentobarbital sodium
injections with 1000 unit heparin via intraperitoneal (i.p.). Maintenance anesthesia was
given 30 mg/kg pentobarbital sodium (i.p.) as needed.
The animal preparation is shown in illustration figures 3 and 4. Initially, a PE-50
polyethylene catheter was inserted into the left carotid artery for monitoring mean
arteriolar blood pressure throughout the entire experiment (see figure 3). Secondly, the
jugular vein was catheterized (24 gauge catheter) superiorly to inferiorly in order to
intravenously infuse different solutions, such as 20%, 30%, 50% D-glucose, 30% Lglucose, or saline (see figure 3). The 20%, 30%, 50% D-glucose, or 30% L-glucose
solution was freshly made by dissolving D-glucose or L-glucose into saline. Different
concentrations of D-glucose solutions were used to induce hyperglycemia at 200 mg/dL,
400 mg/dL, or 600 mg/dL, respectively. Due to the similar structure and weight as well as
inability for the body to metabolize L-glucose, the 30% L-glucose served as an ideal
control group for the 30% D-glucose.
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Figure 3. The catheterization of the jugular vein and carotid artery.
Both femoral veins were exposed and catheterized in order to place randomly a
calibrated NO microsensor or a H2O2 microsensor into each respective femoral vein (see
figure 4). These microsensors were connected to an Apollo 4000 monitor to measure
blood NO and H2O2 levels in real-time. After 1 hour stabilization period to record
baseline readings, saline or glucose solutions was administered at a rate of 0.25 mL/min
for the first four minutes for loading dose, thereafter the infusion speed was maintained at
rate from a range of 0.018 mL/min to 0.035 mL/min based on the target glucose level
throughout the remainder of the experiment. Blood pressure, NO and H2O2 were recorded
at the baseline and at 20 min intervals for a total of 180 min after intravenous infusion of
saline, D-glucose or L-glucose. In every group, blood glucose was recorded from
pricking the tail vein at the beginning and every 40 min through the experiment via
Ascensia Contour blood meter. Moreover, respiratory rate and urination were observed to
monitor the anesthesia status of the rats during the experiment.
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Figure 4. Nitric oxide and hydrogen peroxide microsenors in the femoral veins.

After the experiment, the abdominal aorta and the vena cava were removed and
stored in 4% paraformaldehyde for future analysis of leukocyte vascular adherence. The
thoracic aorta was harvested and frozen for future immunohistochemistry or western blot
analysis of adhesion molecules.
Furthermore, the current changes in NO or H2O2 release during hyperglycemia (in
picoamps) were expressed as change relative to initial baseline. Thereafter, the picoamp
values were converted to the concentration of NO (nM) or H2O2 (µM) after correction to
the calibration curve of free radical microsensors. In order to further clarify the influence
of D-glucose or L-glucose on blood NO and H2O2, data was also expressed as relative
NO or H2O2 change under these conditions by subtracting the NO or H2O2 values of
saline control group at each time point.

Experimental Groups
There were a total of 5 experimental groups in this study:
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1.) Saline control group (n=7 for NO and n=5 for H2O2): The animal had the same
surgery and was monitored the blood NO and H2O2 when saline was intravenously
infused for 3 hours. This group was selected to show the animal can go through the
surgery procedures and maintain stable conditions throughout the whole experiment
period. Moreover, the level of blood NO and H2O2 in this group reflected the real-time
vascular endothelial function and served as control to evaluate the change under
hyperglycemic or hyperosmolarity conditions.
2.) Hyperglycemic group (200 mg/dL, n=7 for NO and n=6 for H2O2): The
animal was intravenously infused with 20% D-glucose in order to maintain
hyperglycemic condition at 200 mg/dl for 3 hours. This group was used to evaluate the
real-time blood NO and H2O2 change at mild hyperglycemic conditions.
3.) Hyperglycemic group (400 mg/dL, n=6 for NO and n=6 for H2O2): The
animal was intravenously infused with 30% D-glucose in order to maintain
hyperglycemic condition at 400 mg/dl for 3 hours. This group was used to evaluate the
real-time blood NO and H2O2 change at moderate hyperglycemic conditions.
4.) Hyperglycemic group (≥600 mg/dL, n=6 for NO and n=6 for H2O2): The
animal was intravenously infused with 50% D-glucose in order to maintain
hyperglycemic condition at ≥600 mg/dl for 3 hours. This group was used to evaluate the
real-time blood NO and H2O2 change at severe hyperglycemic conditions.
5.) 30% L-glucose group (n=5 for NO and n=5 for H2O2): L-glucose is the
enantiomer of D-glucose and cannot be synthesized or metabolized by living organisms
as a source of energy. 30% L-glucose has the same osmolarity as 30% D-glucose.
Therefore, this group serves as another control for the 30% D-glucose group to indicate if
high osmolarity is also involved in the change of blood NO and H2O2 under
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hyperglycemic conditions induced by D-glucose.

Statistics
All data in text and figures is represented as mean ± SEM. When comparing
more than two groups, the analysis was done by ANOVA using post hoc analysis with
the Bonfferoni/Dunn test to detect differences among experimental groups within each
group. Probability values of <0.05 are considered to be statistically significant.
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Results
The rats exhibited the normal vital signs for all groups throughout the
experimental period. The blood pressure (BP) ranged from 90-130 mm Hg throughout
the entire experiment except for the slight increase about 10-15 mmHg in blood pressure
during the first 5 min of 50% D-glucose infusion. However, after 5 min, the blood
pressure then subsided and remained stable throughout the experiment. In the
hyperglycemic and L-glucose groups, the rat started to urinate from 20-40 min after
glucose infusion to the 180 min of infusion.

Blood glucose levels in experimental groups
The blood glucose levels in every experimental group are shown in figure 5. The
baseline of blood glucose ranged from 79-92 mg/dL and there was not significant among
the groups. Infusion of saline for 180 min slightly raised blood glucose to 100±7 mg/dL
at the end of the experiment.
Blood glucose was increased to 197±34 mg/dL after 20 min infusion of 20% Dglucose. Thereafter, the blood glucose was maintained around 200 mg/dL, showing
245±35 mg/dL at 60 min, 279±34 mg/dL at 100 min, 268±38 mg/dL at 140 min, and
247±25 mg/dL at 180 min of the continuous infusion. In 30% D-glucose infusion group,
blood glucose was raised to 367±18 mg/dL after 20 min infusion. Thereafter, the blood
glucose was kept around 400-500 mg/dL with continuous infusion. Blood glucose was
363±37 mg/dL at 60 min, 481±50 mg/dL at 100 min, 523±40 mg/dL at 140 min, and
428±30 mg/dL at 180 min of the continuous infusion. In contrast, the 30% L-glucose
infusion did not dramatically increase blood glucose levels compared to 30% D-glucose,
the blood glucose at 180 min was about 129±15 mg/dL. This indicated that the infusion
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of L-glucose has no effect on changing blood glucose levels because L-glucose cannot be
metabolized as D-glucose. The infusion of 50% D-glucose increased blood glucose to
549±22 mg/dL after 60 min infusion interval. The hyperglycemic condition was then
remained at a range of 552 ± 20 mg/dL at 100 min, 600.0 ± 0 mg/dL at 140 min and 564
±25 mg/dL at 180 min.

Figure 5. The comparison of blood glucose levels among saline, L-glucose
hyperglycemia infusion groups.

Blood H2O2 levels in experimental groups
Hyperglycemic conditions had significantly higher blood H2O2 levels compared
to the saline control and L-glucose groups (Figures 6A and 6B). Figure 6A illustrates the
H2O2 change relative to the baseline among different experimental groups. In the saline
group, the blood H2O2 levels continued to drop and reduced by 4.62±0.34 µM (n=5) at
the end of the 180 min infusion compared to the baseline. In the 200 mg/dL
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hyperglycemic group, blood H2O2 levels stayed significantly higher at 60 min and
remained significantly higher throughout the rest of experiment compared to saline group
(p<0.05, figure 6A). Furthermore, the blood H2O2 in the 400 mg/dL hyperglycemic
groups remained significantly higher at most of the experimental time points (i.e. 20, 60,
80, 100, 120, 140, 160, and 180 min) compared to saline group (p<0.05, figure 6A).
Moreover, there was a dose-dependent effect in increasing blood H2O2 levels between
these two hyperglycemic groups. At 180 min, blood H2O2 levels dropped by 2.22±0.61
µM (n=6) for 200 mg/dL group and by 1.53±0.20 µM (n=6) for 400 mg/dL group relative
to baseline. In contrast, 600 mg/dL hyperglycemic group remained high blood H2O2
levels in the initial 40 minutes then quickly reduced to the similar H2O2 levels as that in
200 mg/dL group. There was no statistical significance between the 600 mg/dL and 200
mg/dL groups. At 180 min, blood H2O2 levels in 600 mg/dL hyperglycemic group
dropped by 2.42±0.37 µM (n=6) relative to baseline. It was noted that blood H2O2 levels
in 400 mg/dL hyperglycemic group ended up the highest out of all the groups. However,
it was not significantly higher when compared to the other hyperglycemic groups. Blood
H2O2 levels in L-glucose group were significantly lower compared to 400 mg/dL
hyperglycemic group at most time intervals except for the 40 min and 140 min intervals
(p<0.05). Moreover, this change was similar as saline control. At 180 min, blood H2O2
level in L-glucose group reduced by 3.75±0.29 µM (n=5) relative to baseline.
Figure 6B shows the time course of H2O2 change in hyperglycemic and L-glucose
infusion groups relative to saline. Compared to saline control group, hyperglycemia
significantly increased blood H2O2 levels at most of time points. By contrast, blood H2O2
levels in L-glucose group remained similar level (i.e. no statistical significant time points)
as saline control throughout the experiment. At 180 min, blood H2O2 levels in 200
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mg/dL, 400 mg/dL, and 600 mg/dL groups were 2.40±0.61 µM, 3.1±0.2 µM, and
2.21±0.37 µM higher than that in saline group, respectively (all p<0.05). The blood H2O2
levels were only 0.88±0.29 µM higher in the L-glucose group compared to the saline
control at the end of the experiment.

A
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Figure 6A & 6B. The comparison of blood H2O2 levels among saline,
hyperglycemia, and L-glucose groups relative to baseline (6A) or relative to saline
group (6B). Hyperglycemic groups exhibited significantly higher blood H2O2 levels
compared to saline control and L-glucose group (*p<0.05, **p<0.01 compared to
saline; #p<0.05, ##p<0.01 compared to L-glucose group). The X axis indicates
duration of experiment and the Y axis indicates the relative change of blood H2O2 in
µM. The number of rats used for each group is indicated next to each labeled group.

Blood NO levels in experimental groups
Hyperglycemic conditions had significantly lower blood NO levels compared to
the saline control and L-glucose groups (Figures 7A and 7B). Figure 7A illustrates the
blood NO levels relative to baseline among the different experimental groups. In the
saline group, blood NO levels remained stable and only slightly decreased by 17.61±8.04
nM (n=7) at 180 min. In the 200 mg/dL hyperglycemic group, blood NO continued to
drop and remained significantly lower level was noted at 160 min and 180 min of
infusion compared to saline group (p<0.05, figure 7A). Furthermore, the blood NO in the
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400 mg/dL hyperglycemic groups decreased immediately after infusion and remained
significantly lower at 100 min, 120 min, 140 min, 160 min and 180 min compared to
saline group (p<0.05, figure 7A). We observed a dose-dependent effect in reducing blood
NO levels between the 200 mg/dL and the 400 mg/dL hyperglycemic groups. At 180
min, blood NO levels decreased by 88.91±17.90 nM (n=7) for 200 mg/dL group and by
129.76±15.28 nM (n=6) for 400 mg/dL group relative to baseline. By contrast, 600
mg/dL hyperglycemic group showed an initial NO increase at 20 min of infusion, then
rapidly dropped below baseline at 60 min and remained significantly lower from 120 min
to the end of the experiment compared to the saline control (p<0.05, figure 7A). At 180
min, blood NO levels in 600 mg/dL hyperglycemic group dropped by 123.59±23.45 nM
(n=6) relative to baseline, which was similar (i.e. no statistical significance) to the NO
levels in 400 mg/dL hyperglycemic group. Blood NO levels in L-glucose group were
significantly higher compared to 400 mg/dL hyperglycemic group from 80 min to 180
min of infusion (p<0.05, see Fig 7A), which was similar as saline control in that there
was not any statistical significance between the L-glucose and the saline control at any
time point. At 180 min of infusion, blood NO levels in L-glucose group slightly changed
by 6.03±22.01 nM (n=5) relative to baseline.
The blood NO levels were also analyzed by calculating the change in blood NO
levels under hyperglycemia or L-glucose relative to saline control group at each time
point (see figure 7B). Hyperglycemia significantly decreased blood NO levels at time
points 100-160 min. There was no statistical significant difference between blood NO
levels in L-glucose group and the saline control throughout the entire experiment. At 180
min, blood NO levels in 200 mg/dL, 400 mg/dL and 600 mg/dL groups were 71.3±17.9
nM, 112.15±15.28 nM and 105.98±23.45 nM lower than that in saline group, respectively
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(p<0.01). By contrast, the blood NO levels were only 11.58±22.01 nM (n=5) higher
compared to the saline control at 180 min of infusion of 30% L-glucose.

A
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Figure 7A & 7B. The comparison of blood NO levels among saline, hyperglycemia,
and L-glucose groups relative to baseline (7A) or relative to saline group (7B).
Hyperglycemic groups exhibited significantly lower blood NO levels compared to
saline control and L-glucose group (*p<0.05, **p<0.01 compared to saline; #p<0.05,
##p<0.01 compared to L-glucose group). The X axis indicates duration of
experiment (i.e. time in minutes) and the Y axis indicates the concentration of blood
NO in nM. The number of rats used for each group is indicated next to each labeled
group.
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Discussion
Summary of Results
The major findings of this study were: first, intravenous infusion of 20%, 30%,
and 50% of D-glucose induced 200 mg/dL, 400 mg/dL, and 600 mg/dL hyperglycemia,
respectively, and the different degree of hyperglycemia conditions was maintained for
180 min with continuous infusion. Second, under hyperglycemic conditions, blood H2O2
levels were significantly higher as compared to the saline control group. Third, by
contrast, blood NO levels were significantly lowered under hyperglycemic conditions
starting at 100 min through the rest of the hyperglycemic period as compared to the saline
control group. Finally, 30% L-glucose exhibited significantly lower blood H2O2 and
higher blood NO levels compared to 30% D-glucose, but no statistical significant
difference was noted between this group and the saline control.

Acute Hyperglycemic rat model
We established a successful acute hyperglycemia induced vascular dysfunction rat
model by measuring blood NO and H2O2 levels in real-time. The hyperglycemic rat
model was based on the rat model used by Saha et al. (Saha, Xia et al. 2006), who
showed that initial bolus injection of 20% glucose producing the maximum acute increase
in blood glucose level (about 200 mg/dL). This increase was maintained as long as the
rats received continuous glucose infusion (Saha, Xia et al. 2006). Therefore, we also used
the bolus infusion of 1 ml D-glucose or L-glucose solution within 4 min for loading dose.
Then the infusion rate was reduced by 10 fold to maintain the target blood glucose
concentration throughout the 180 min experiment. Our blood glucose measurement
showed that this infusion method can reach 200 mg/dL, 400 mg/dL or 600 mg/dL
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hyperglycemic conditions around 20-60 min after D-glucose infusion and stayed
relatively constant for the rest of experiment. In contrast, 30% L-glucose infusion did not
cause high blood glucose which differed from the 30% D-glucose group and showed
similar blood glucose levels as the saline group. Animals in all groups had relatively
stable conditions with respect to the respiratory rate and BP. It was noted that there was
initial increase of BP about 10-15 mmHg when the rats received the bolus injection of
50% D-glucose. This was maybe due to the activation of sympathetic nervous system
responding to the excessively high concentration of D-glucose (Villafana, Huang et al.
2004). Under hyperglycemic conditions, rats urinated from 20-40 min to the end of
infusion. This urination was also observed in L-glucose infused rats. Since 30% Lglucose had a similarly high osmolarity as 30% D-glucose, this data indicated that
hyperosmolarity was the major cause of urination in the rats.

Increased Levels of H2O2 under Acute Hyperglycemic Conditions
We have demonstrated that H2O2 could serve as an indicator of the amount of SO
produced under different pathophysiological conditions, such as ischemia-reperfusion
(I/R) (Chen, Kim et al. 2010). In this study, H2O2 levels had dropped approximately 5µM
within 180 min in the saline group. This phenomenon was most likely attributed to the
decreased body temperature when the anesthetized rat was placed on a thermostatic board
for almost 240 min. This H2O2 drop had also been observed in femoral I/R and lithotripsy
rat models (Chen, Kim et al. 2010; Chen, Rueter et al. 2011). All hyperglycemic groups
had a significantly higher blood H2O2 levels compared to saline control. The increased
oxidative stress immediately occurred from the beginning of the intravenous infusion of
high concentration D-glucose. Furthermore, the 200 mg/dL and 400 mg/dL
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hyperglycemia groups demonstrated a dose-dependent effect on increasing blood H2O2
levels. This data was consistent with findings by Iori et al (Iori, Pagnin et al. 2008). Iori
showed that the 20 mM glucose incubation induced a higher ROS production than the 10
mM glucose incubation cultured human endothelial cells.
Furthermore, we found that the 600 mg/dL hyperglycemia group had the highest
H2O2 levels observed in only the first 20 min and then dropped off to levels similar H2O2
levels as 200 mg/dL at the end of the experiment. This may be due to the excessively
high glucose, which may quickly damage the body system, such as causing cell death and
inhibiting enzymes activity in the body. In Iori’s experiment, he also found that the
endothelial cells exposed to 20mM glucose had about 1.5 fold higher incidence of
apoptosis as compared to the 10mM glucose group. Additionally, the activity of enzyme
(i.e., heme oxygenase-1) was also reduced to a greater degree in 20 mM glucose (Iori,
Pagnin et al. 2008).
The 30% L-glucose group, which has the same osmolarity as 30% D-glucose,
exhibited significantly lower blood H2O2 levels compared to 400 mg/dL group which was
infused with 30% D-glucose. The L-glucose is an isomer of glucose, and cannot be
synthesized or metabolized by the body. Therefore, 30% L-glucose infusion group served
as a control to test if hyperosmolarity also played a role in hyperglycemia induced blood
H2O2 change. Our data suggests that high osmolarity caused by L-glucose infusion does
not significantly contribute the hyperglycemia-induced oxidative stress. Similarly,
Nakahata et al. also found that 20 mM D-glucose, not 20 mM L-glucose, significantly
increased SO production in cerebral arteries after 60 min incubation (Nakahata, Kinoshita
et al. 2008). This data supports the rationale that hyperglycemia-induced oxidative stress

33
and endothelial dysfunction are the subsequent events after D-glucose circulates in blood
vessels and is utilized (Ding H and 2010).

Decreased Levels of Blood NO under Hyperglycemic Conditions
Blood NO levels in our saline group were relatively stable and only slightly
dropped (by approximately 17 nM) relative to the baseline within the 180 min infusion
period. The stability of blood NO in anesthetized rats had been observed in our femoral
I/R and lithotripsy animal models (Chen, Kim et al. 2010; Chen, Rueter et al. 2011). In
contrast to saline control, hyperglycemia significantly decreased blood NO levels in a
dose-dependent manner between 200 mg/dL and 400 mg/dL. The 600 mg/dL
hyperglycemia had an initial spike increase in NO production, and then quickly decreased
when hyperglycemic condition was maintained. The initial increase of NO followed the
BP increase caused by the bolus infusion of 50% D-glucose. Both events may be due to
the activation of sympathetic nervous system to increase the secretion of epinephrine and
norepinephrine, which further enhance BP and insulin secretion (Villafana, Huang et al.
2004).
Postprandial hyperglycemia has been highlighted in non-diabetic subjects because
it can induce vascular endothelial dysfunction (Ceriello, Hanefeld et al. 2004). Kawano
et al. found that the post-challenge hyperglycemia after oral glucose tolerance test rapidly
suppressed endothelium-dependent vasodilation, probably through increased production
of oxygen-derived free radicals in healthy subjects (Kawano, Motoyama et al. 1999). Our
data by measuring blood NO levels provides clear evidence showing that acute
hyperglycemia significantly reduces endothelial-derived NO bioavailability. The blood
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NO measured during 180 min experimental period is not produced from iNOS because
the synthesis of iNOS needs longer time than 180 min.
It is noted that there exists a negative relationship between H2O2 and NO. This is
because increased superoxide production can directly quench NO. In our study, 400
mg/dL exhibited the highest blood H2O2 level associated with the lowest blood NO level.
Moreover, the time course in significant changes of blood NO and H2O2 were different.
H2O2 levels in the hyperglycemic groups (i.e., 400 mg/dL) were significantly higher at 20
min of infusion throughout the rest of 180 min experimental period compared to saline
control. By contrast, NO levels in the hyperglycemic groups (i.e., 400 mg/dL) started a
significant drop from 100 min to 180 min of the experiment compared to saline control.
This discrepancy suggests that oxidative stress occurs relatively rapidly, then it will
further reduce endothelial-derived NO levels. Cai et al. has showed that hyperglycemia
resulted in a decrease in NO production by an increase in superoxide production which
further causes BH4 deficiency and eNOS uncoupling (Cai and Harrison 2000).

Mechanisms related to hyperglycemia-induced blood NO and H2O2 changes
Overview
A key factor to hyperglycemia-induced vascular endothelial dysfunction is
oxidative stress. In this study we measured blood H2O2 levels and found that there existed
oxidative stress under hyperglycemic conditions. It was suggested that the sources of
oxidative stress under hyperglycemia include NADPH oxidase, uncoupled eNOS, and the
mitochondria (Fonseca, Ravi et al.; Brownlee 2001; Forstermann and Munzel 2006).
Moreover, all three sources were suggested to cumulatively produce excess SO in a state
of hyperglycemia. Thereafter, SO will directly quench NO to form peroxynitrite and
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reduce NO bioavailability. SO can also be further converted to H2O2 by SOD. Both
peroxynitrite and H2O2 can cause eNOS uncoupling. Uncoupled eNOS will produce SO
instead of NO to facilitate oxidative stress. Then, more SO can in turn uncouple more
eNOS. This interaction between NO and oxidative stress may cause a vicious and
detrimental cycle (see figure 8). This detrimental cycle can further cause vascular
dysfunction, persistent inflammation, and tissue/organ damage. Furthermore, this cycle
may provide a rationale to explain that H2O2 was significantly increased from the
beginning of hyperglycemia, whereas NO did not significantly decrease until a later time
of this experiment.
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Figure 8. Model of vicious cycle under hyperglycemic conditions. An overview of
the mechanism of how the generation of free radicals from hyperglycemia can cause
a continuous production of more free radicals.

NADPH Oxidase
NADPH oxidase is a membrane bound and cytosolic enzyme producing
superoxide by the utilization of NADPH. In addition to neutrophils, NADPH oxidase also
presents in endothelial cells, vascular smooth muscle cells, and other cells. The
physiological NADPH oxidase derived SO has been implicated in the regulation of
vascular tone, vascular cell growth, migration, proliferation, and activation (Touyz 2003;
Cai 2005). However, if NADPH oxidase is upregulated, higher amounts of SO may result
in oxidative stress. Numerous studies have indicated that high glucose levels can activate
the enzyme protein kinase C (PKC) in vascular cells. High glucose might stimulate SO

37
production through PKC-dependant activation of NADPH oxidase in vascular cells
(Inoguchi, Li et al. 2000). Inogouchi et al. found that exposure of aortic endothelial cells
to a high glucose level (400 mg/dL) for 72 hrs induced a significant increase in free
radical production as opposed to cells that were exposed only to a glucose level of 100
mg/dL (Inoguchi, Li et al. 2000). Inogouchi also found that the increase in free radical
production was negated through the use of diphenylene iodonium, a NADPH oxidase
inhibitor (Inoguchi, Li et al. 2000). These results from Inoguchi suggest that high glucose
levels may stimulate ROS production through the activation of NADPH oxidase.
Furthermore, it has been found that SO production is significantly increased in
streptozotocin-induced diabetic rats 2 weeks after the onset of diabetes. By contrast,
NADPH oxidase inhibitor or PKC inhibitor can significantly attenuate this oxidative
stress (Sonta, Inoguchi et al. 2004). It will be very interesting for us to investigate if a
NADPH oxidase inhibitor can attenuate the blood H2O2 increase/NO decrease in this
acute hyperglycemia model in the near future.

Uncoupled eNOS
Normally, in the presence of co-factor, BH4, eNOS can keep electron transfer
coupled with oxidation of L-arginine and then generate NO, which is defined as eNOS
coupling (Schmidt and Alp 2007). Moreover, BH4 and the amino acid L-arginine can
stabilize eNOS dimer structure which has catalytic function (Fonseca, Ravi et al.). When
BH4 is oxidized to BH2, BH2 occupies the eNOS oxygenase domain, and blocks electron
transfer to L-arginine, eNOS becomes uncoupled and dissociates to become a monomer,
and then generates SO instead of NO (Vasquez-Vivar, Kalyanaraman et al. 1998).
Fonseca et al. found that H2O2 can induce a collapse in the eNOS dimer resulting in

38
eNOS uncoupling (Fonseca, Ravi et al.). Additionally, the overproduced SO under
hyperglycemia can bind NO to form the peroxynitrite. Peroxynitrite is very potent in
oxidizing BH4 to BH2 resulting in decreased BH4 to BH2 ratio. Thereafter, eNOS
becomes uncoupled and produce SO instead of NO (Crabtree, Smith et al. 2008). Thereby
it is evident that a vicious cycle of oxidative stress under hyperglycemia can propagate:
increased SO production directly reduces NO bioavailability by forming peroxynitrite.
Moreover, peroxynitrite and H2O2 further cause eNOS uncoupling to produce SO instead
of NO. Thereafter, more SO is generated, whereas less NO is produced. This process can
keep repeating and can cause serious damage on vascular endothelial function. Therefore,
uncoupled eNOS can be another source subsequent to oxidative stress induced by
hyperglycemia to further exacerbate blood NO and H2O2 changes and vascular
endothelial dysfunction. This vicious cycle can also help explain the time difference in
blood NO and H2O2 significant changes found in this hyperglycemic study.

Mitochondrial SO production
Oxidative phosphorylation to generate ATP is the most prominent function of
mitochondria. The system of oxidative phosphorylation includes five large multienzyme
complexes. In normal physiological conditions and in most tissues, this system is an
important source of SO. Meanwhile, SOD inside mitochondria can remove the SO to
protect the mitochondria. Under hyperglycemia, it is hypothesized that there exists the
increased hyperglycemia-derived electron donors from the TCA cycle (NADH and
FADH2), increases the mitochondrial membrane potential. This increased membrane
potential inhibits electron transport at complex III, increasing the half-life of free-radical
intermediates of co-enzyme Q, which reduce O2 to SO (Brownlee 2001). This has been
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proved by Srinivasan et al. They found that chronic exposure of human aortic endothelial
cells to elevated glucose (25 mM) reduced total nitrite levels, eNOS mRNA and eNOS
protein. This effect was reduced by the specific inhibition of reactive oxygen species
production through the mitochondrial electron transport chain (Srinivasan, Hatley et al.
2004). These findings demonstrate that another possible source of SO under
hyperglycemic condition is from the mitochondria.

D-glucose scavenging of NO
Moreover, in vitro, hyperglycemia can also be another factor in the significant
decrease of NO. Brodsky et al. found that glucose can directly quench NO by the direct
scavenging effect. He also correlated a link of diminished availability of NO in blood
vessels when they were exposed to glucose. Furthermore, Brodsky provided experimental
evidence showing that the healthy human subjects had a small, but significant reduction
in NO-mediated vasoactivity when blood glucose was elevated to 270 mg/dL (Brodsky,
Morrishow et al. 2001). This could serve as another possible factor to explain the drop in
blood NO levels under acute hyperglycemic conditions.

Limitations/Future Studies
In this study, the blood NO and H2O2 levels were analyzed relative to the baseline
or saline group. The free radical microsensor was calibrated before the experiment to test
the sensitivity. Moreover, the correct poise voltage setup can also warrant the accuracy of
the microsensors by defining the appropriate range for NO and H2O2 measurements.
After the experiments, blood was collected and we plan to conduct fluorescence Griess
Assay to measure the blood nitrite levels to confirm our NO data. Furthermore, blood

40
malondialdehyde concentration is also needed to reflect systemic lipid oxidation due to
oxidative stress induced by hyperglycemic conditions.
We did appreciate that there may exist hyperinsulinemia in hyperglycemic rats.
Our hyperglycemic rat model is induced in normal rats with normal insulin secretion
responding to blood glucose change. It has been shown that hyperinsulinemia can cause
less SO and more NO production. However, due to the continuation of D-glucose
infusion, the excessive amount of D-glucose overrides on the effects of insulin to
maintain hyperglycemic conditions. Therefore, the blood NO and H2O2 changes
observed by this study can still indicate the detrimental effects on vascular function by
hyperglycemia.
Furthermore, this is a pilot study to establish the acute hyperglycemic rat model
and measure blood NO and H2O2 changes in real-time. We found that hyperglycemia
maintained significantly higher H2O2 levels associated with significantly lower blood NO
levels. It has been suggested that NADPH oxidase and eNOS uncoupling may be the
important sources for these changes. Therefore, the further studies are needed to explore
these related mechanisms by using NADPH oxidase inhibitor (diphenylene iodonium), or
coupled eNOS cofactor (BH4), or coupled eNOS substrate (L-arginine) with D-glucose
infusion.

Conclusion
In summary, this study established an acute hyperglycemia-induced vascular
dysfunction rat model by measuring blood NO and H2O2 levels in real-time. We found
that acute hyperglycemia had a significantly higher blood H2O2 levels associated with
significantly lower blood NO levels. The oxidative stress occurred immediately after
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induction of hyperglycemia, whereas reduced endothelial-derived NO bioavailability
took place at the later time points of hyperglycemia. This study indicates that oxidative
stress is a predecessor of vascular endothelial dysfunction under hyperglycemic
conditions and suggests that acute hyperglycemia for 180 min increased oxidative stress
and reduced endothelial-derived NO bioavailability, which may not be due to high
osmolarity.

Clinical Relevance
As stated in the introduction, hyperglycemia is linked to vascular endothelial
dysfunction by increasing oxidative stress. Prolonged oxidative stress and vascular
endothelial dysfunction most likely contribute to cardiovascular disease and
atherosclerosis. The purpose of this pilot study was to establish a hyperglycemic model to
test the relevant mechanisms to help prevent vascular dysfunction and other circulatory
complications in diabetic and non-diabetic individuals. Hyperglycemia has been linked to
the progression diabetic nephropathy. Hyperglycemia caused a production of reactive
oxygen species that caused morphological and functional changes in mouse podocytes
(Piwkowska, Rogacka et al.). It is also important to maintain normal glucose levels
during surgery to avoid blood clots and stoke as well. Another factor that can cause
hyperglycemia is psychological stress. To avoid future vascular complications, it is
important for an individual to eliminate chronic psychological stress.
This could also bring awareness to the public about the hazards of postprandial
hyperglycemia. It is a well known that consumption of excess dietary saturated fat and
dietary sodium is directly linked to heart diseases. To promote better health, some
individuals place some dietary restrictions on dietary fat and sodium. However, sugars
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such as those found in soda, candy, etc. are not commonly seen through the eyes of the
public as hazardous to heart health. It is known that a 20 oz bottle of the leading grape
soda contains 81 g of sugar. When consuming a 20 oz bottle of this soda, one should
anticipate similar vascular function changes as to the individuals in the 75 g post oral
glucose challenge test mentioned in the introduction. This study provides the basic
evidence for public to raise the awareness of the possible harmful impact of a high sugar
diet on vascular function.
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